TEL AVIV, Feb 13 (Reuters) - Israel-based Teva Pharmaceutical Industries said on Tuesday it had anticipated and planned for a second generic competitor to its multiple sclerosis treatment Copaxone to enter the market in 2018.



Latest News

Jpost: Amazing Grace at President’s Residence

NewYorkTimes: George R. R. Martin Answers Times Staffers’ Burning Questions

NewYorkTimes: Round Table: 3 Writers on the Emotional Toll of Being Undocumented

FOX: Laura Ingraham: Midterm madness -- Elizabeth Warren, other Dems embrace victimhood as a political platform

FOX: Rusty 1958 Porsche 356 stored for 35 years worth small fortune

CNN: Inside Georgia Democrats' 'voter protection' war room

CNN: Why robocalls are about to get more dangerous

CNN: CNN poll: Cruz leads O'Rourke with three weeks to go

CNN: Sessions slams legal discovery process against officials

CBC: No chance Congress will vote on USMCA this year, Mitch McConnell says

BBC: RAF Hercules in near-miss with coastguard helicopter in Highlands

BBC: Nations League: Ciaran Clark out of Republic of Ireland's Wales game

BBC: Herefordshire firm launches biodegradable crisp packet

ABC: Tagovailoa one of 5 Alabama midseason AP All-Americans

Los Angeles Times: Football: Week 9 schedule

Los Angeles Times: Pip Pip Hooray: Pippa Middleton gives birth to baby boy

USA Today: Battle of the weepies: Nicholas Sparks v. Mitch Albom. Who made us cry more?

USA Today: Facebook bans misinformation about voting ahead of midterm elections

USA Today: Facebook bans misinformation about voting ahead of midterm elections

USA Today: Stock market rebounds: Strong earnings from Dow companies provide boost

USA Today: UEFA charges Romania for racism, misconduct by fans

USA Today: Giants owner John Mara: Odell Beckham Jr. needs to do 'more playing' and 'less talking'

USA Today: Wyoming looks to regroup from losing streak